The Addition of Concurrent Immune Checkpoint Inhibitors for Chemoradiotherapy With Consolidative Immune Checkpoint Inhibitors in Unresectable Cancers: A Systematic Review and Meta-Analysis.
Xu Tong, Zhenting Liu, Xiaoxiang Zhou et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy and safety of adding concurrent immune checkpoint inhibitors (ICIs) to chemoradiotherapy (CRT) followed by consolidative ICIs in patients with unresectable cancers. The analysis included 13 randomized controlled trials (RCTs) with 6868 patients. Results indicated that while CRT with consolidative ICIs improved overall survival (OS) and progression-free survival (PFS), the addition of concurrent ICIs did not enhance these outcomes compared to CRT alone.
Key findings
- Patients receiving CRT with consolidative ICIs had a significantly improved OS (HR 0.743) compared to CRT alone.
- Progression-free survival (PFS) was also significantly better with CRT and consolidative ICIs (HR 0.674) versus CRT alone.
- Adding concurrent ICIs did not significantly improve OS (HR 0.942) or PFS (HR 0.880) compared to CRT alone.
- Significant differences in OS and PFS were observed between CRT with consolidative ICIs and CRT with concurrent plus consolidative ICIs.
Why it matters
Understanding the impact of concurrent ICIs on treatment outcomes is crucial for optimizing therapeutic strategies in unresectable cancers. This study suggests that concurrent ICIs may not provide additional benefits and could potentially diminish the advantages of consolidative ICIs.